Radiopharmaceuticals (Theragnostics)
Prostate Cancer, Neuroendocrine Tumors
Clinical/CommercialActive
Key Facts
Indication
Prostate Cancer, Neuroendocrine Tumors
Phase
Clinical/Commercial
Status
Active
Company
About Jubilant Pharmova
Jubilant Pharmova's mission is to become a leading global pharmaceutical company by delivering high-quality, affordable medicines through innovation and operational excellence. The company has achieved this through strategic vertical integration, building world-class manufacturing assets for complex APIs and sterile injectables, and establishing a strong global footprint. Its core strategy focuses on deepening capabilities in high-growth specialty segments like oncology and radiopharmaceuticals, while expanding its high-margin Contract Development and Manufacturing (CDMO) business to leverage global outsourcing trends.
View full company profileTherapeutic Areas
Other Prostate Cancer, Neuroendocrine Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Lu-177 Supply Partnerships | Eckert and Ziegler | Commercial & Clinical Support |